ClinicalTrials.gg
CompletedNCT01452750Updated Feb 5, 2014

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

A Phase 3 interventional study of TAK-438 and Placebo in Gastric Ulcers and Duodenal Ulcers, sponsored by Takeda. Completed at 102 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-02-05.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.

Enrollment
Largest of 10
642 · median 320
Started
2011
with 3 others
Phase 3
8 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
Takeda

Among the 10 studies testing vonoprazan in Stomach Ulcer, this one has the largest enrollment, is one of 4 that started in 2011, is one of 8 in phase 3, and was the 1st registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Stomach Ulcer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).

03

Conditions studied

  • Gastric Ulcers
  • Duodenal Ulcers

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who require continuous NSAID therapy during the treatment period with the study drug
  2. Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed
  3. Outpatient (including inpatient for examinations)

Exclusion criteria

Exclusion Criteria:

  1. Participants scheduled to change the type and dosage regimen of NSAID
  2. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed
  3. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
  4. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
  5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  6. Participants with a previous or current history of aspirin-induced asthma
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
642 participants (actual)

Study arms

  • Experimental
    TAK-438 10 mg QD

    Drug: TAK-438 · Drug: Placebo

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438 · Drug: Placebo

  • Active comparator
    Lansoprazole 15 mg QD

    Drug: Lansoprazole · Drug: Placebo

Interventions

  • TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.

  • DrugPlacebo

    Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

  • TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.

  • DrugPlacebo

    Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

  • Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.

    Also known as: AG-1749

  • DrugPlacebo

    TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.

06

What researchers measure

Primary outcomes

  1. Recurrence rate of gastric or duodenal ulcer within 24 weeks

    Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers. Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.

    Time frame: 24 weeks

Secondary outcomes

  1. Recurrence rate of gastric or duodenal ulcer within 12 weeks

    Time frame: 12 weeks

  2. Gastric mucosal injury

    Time frame: 24 Weeks

  3. Duodenal mucosal injury

    Time frame: 24 weeks

  4. Occurrence rate of hemorrhagic lesion in stomach or duodenum

    Time frame: 24 weeks

  5. Time to recurrence of gastric or duodenal ulcer

    Time frame: 24 weeks

07

Study locations

102 sites
  • Kasugai-shi, Aichi, Japan
  • Nagoya-shi, Aichi, Japan
  • Seto-shi, Aichi, Japan
  • Akita-shi, Akita, Japan
  • Funabashi-shi, Chiba, Japan
  • Ichihara-shi, Chiba, Japan
  • Nagareyama-shi, Chiba, Japan
  • Matsuyama-shi, Ehime, Japan
  • Niihama-shi, Ehime, Japan
  • Saijo-shi, Ehime, Japan
  • Fukui-shi, Fukui, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Itoshima-shi, Fukuoka, Japan
  • Kitakyusyu-shi, Fukuoka, Japan
  • Munakata-shi, Fukuoka, Japan
  • Onga-gun, Fukuoka, Japan
  • Tagawa-shi, Fukuoka, Japan
  • Yukuhashi-shi, Fukuoka, Japan
  • Fukushima-shi, Fukushima, Japan
  • Koriyama-shi, Fukushima, Japan
  • Gifu-shi, Gifu, Japan
  • Mebashi-shi, Gunma, Japan
  • Takasaki-shi, Gunma, Japan
  • Fukuyama-shi, Hiroshima, Japan
  • Hatsukaichi-shi, Hiroshima, Japan
  • Higashihirosima-shi, Hiroshima, Japan
  • Asahikawa-shi, Hokkaido, Japan
  • Hakodate-shi, Hokkaido, Japan
  • Obihiro-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Sunagawa-shi, Hokkaido, Japan
  • Tomakomai-shi, Hokkaido, Japan
  • Akashi-shi, Hyogo, Japan
  • Himeji-shi, Hyogo, Japan
  • Itami-shi, Hyogo, Japan
  • Kako-gun, Hyogo, Japan
  • Kato-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Higashiibaragi-gun, Ibaragi, Japan
  • Koga-shi, Ibaragi, Japan
  • Mito-shi, Ibaragi, Japan
  • Hitachi-shi, Ibaraki, Japan
  • Hakusan-shi, Ishikawa, Japan
  • Komatsu-shi, Ishikawa, Japan
  • Takamatsu-shi, Kagawa, Japan
  • Kamakura-shi, Kanagawa, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Uji-shi, Kyoto, Japan
  • Tsu-shi, Mie, Japan
  • Sendai-shi, Miyagi, Japan
  • Matsumoto-shi, Nagano, Japan
  • Nagano-shi, Nagano, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Ikoma-shi, Nara, Japan
  • Nara-shi, Nara, Japan
  • Nigata-shi, Nigata, Japan
  • Beppu-shi, Oita, Japan
  • Oita-shi, Oita, Japan
  • Yuhu-shi, Oita, Japan
  • Kurashiki-shi, Okayama, Japan
  • Higashiosaka-shi, Osaka, Japan
  • Moriguchi-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Osakasayama-shi, Osaka, Japan
  • Tondabayashi-shi, Osaka, Japan
  • Ogi-shi, Saga, Japan
  • Saga-shi, Saga, Japan
  • Ageo-shi, Saitama, Japan
  • Hiki-gun, Saitama, Japan
  • Kasukabe-shi, Saitama, Japan
  • Kumagaya-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Sayama-shi, Saitama, Japan
  • Toda-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Otsu-shi, Shiga, Japan
  • Izumo-shi, Shimane, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Naruto-shi, Tokushima, Japan
  • Adachi-ku, Tokyo, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Hachiouji-shi, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Mitaka-shi, Tokyo, Japan
  • Musashimurayama-shi, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Sumida-ku, Tokyo, Japan
  • Yonago-shi, Tottori, Japan
  • Tonami-shi, Toyama, Japan
  • Toyama-shi, Toyama, Japan

Showing the first 100 of 102 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7. PubMed 28988197 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2011
First posted
Oct 17, 2011
Start
Oct 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Feb 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01452750
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Oct 2011
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Feb 5, 2014

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion